Collaborations

Partnering to advance groundbreaking programs in precision oncology

We are committed to partnering with the best and brightness minds in academia, biotechnology and pharma to advance programs in targeted/precision oncology. We partner with teams that share our vision to advance promising programs in potentially lethal diseases where the unmet need remains frustratingly high.

We are actively seeking opportunities to collaborate in any of the following areas:

  • Precision oncology programs across solid tumors
  • Neuro-oncology programs that select for genetically defined tumors
  • Novel mechanisms of action; either first-in-class or potentially best-in-class
  • Both pre-clinical and clinical stage assets

The management team at Chimerix has substantial experience in oncology drug development, manufacturing scale up and global regulatory expertise to accelerate precision oncology programs to approval. For more information about how we might work together, please contact Mike Andriole, Chief Business Officer, at [email protected].

Key benefits of collaborating with Chimerix include:

  • Strong culture of execution
  • Extensive clinical development and regulatory experience
  • Creativity in constructing partnerships
  • Commitment to professional alliance management
  • Track record of pioneering novel therapeutic targets for molecularly-defined diseases
Mike Andriole, Chief Business Officer

“Chimerix has a long history of partnerships to develop novel and/or first-in-class treatments for patients globally. Through our collaborations, we aim to leverage the unique strengths of both organizations to accelerate programs to approval and commercialization. Our experience with diverse partnerships across large pharmaceutical companies, smaller biotechs, geographic partnerships, government agencies and academic research institutions all have a common thread: we invest wisely, operate with high integrity, impart a sense of urgency and we are honest about where the data lead us.”

Ongoing Strategic Transactions and Collaborations

CR Pharmaceutical
Emergent
Ohara
Oncoceutics
Pacific Pediatric
Readdi